Open AccessRetinoic acid preparations in the complex treatment of acute promyelocytic leukemia
Author(s) -
Valeriia Cherepanova,
N. A. Medvedeva,
L. N. Tarasova,
Е. П. Сведенцов,
A. V. Kudryavtseva,
V. A. Hovsepyan,
G. K. Platonov,
V. N. Minakov,
A. I. Kostin
Publication year - 2022
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17816/kazmj96225
Subject(s) - promyelocyte , acute promyelocytic leukemia , retinoic acid , medicine , aplasia , tretinoin , hemostasis , gastroenterology , incidence (geometry) , bone marrow , chemistry , biochemistry , physics , optics , gene
The results of the treatment of 11 patients with acute promyelocyte leukosis using the retinoic acid drugs (ATRA, 13-cis-retinoic acid) are presented. Total remission was achieved in 6 out of 9 patients within 2239 days of treatment: in 2 patients on ATRA monotherapy and in 4 patients in combination with polychemotherapy. Normalization of hemostasis indices with tendency to hypercoagulation is noted during the first week. Cupping of hemorrhages took place within 1430 days of treatment. High incidence (67%) of the retinoic acid syndrome is noted. It is connected with the initial hyperleukocytosis and not always timely prescription of polychemotherapy. Less dramatic nature of the disease course, fast cupping of hemorrhages, absence of the bone marrow aplasia phase, decrease of demand in transfusional provision were observed in using ATRA.